Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis

Clinical and Experimental Medicine

Volumn 16, Issue 3, 2016, Pages 413-421

  Zhang, Yong ^a   Guo, Mingfeng ^b   Xin, Ning ^c   Shao, Zhen ^a   Zhang, Xiuying ^a   Zhang, Yanyan ^a   Chen, Jing ^a   Zheng, Shuangshuang ^a   Fu, Linlin ^a   Wang, Yu Zhong ^d   Zhou, Dongmei ^a   Chen, Hao ^a   Huang, Yan ^a   Dong, Ruiguo ^a   Xiao, Chenghua ^a   Liu, Yonghai ^a   Geng, Deqin ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d JINING MEDICAL UNIVERSITY   (China)

Author keywords

IL 17; IL 7; MicroRNAs; MiR 181c; Myasthenia gravis

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 7; LUCIFERASE; MICRORNA; MICRORNA 181C; UNCLASSIFIED DRUG; IL17A PROTEIN, HUMAN; IL7 PROTEIN, HUMAN; MIRN181 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CYTOKINE RESPONSE; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA BINDING; TRANSCRIPTION REGULATION; AGED; BLOOD; CHEMISTRY; MONONUCLEAR CELL; PATHOLOGY; SERUM;

ADULT; AGED; DOWN-REGULATION; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKIN-7; LEUKOCYTES, MONONUCLEAR; MALE; MICRORNAS; MIDDLE AGED; MYASTHENIA GRAVIS; SERUM;

EID: 84929180271     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-015-0358-1     Document Type: Article

References (39)

1. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol. 2002;2(10):797–804.
2. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475–90.
3. Berrih-Aknin S. Myasthenia gravis: Paradox versus paradigm in autoimmunity. J Autoimmun. 2014;52:1–28.
4. O’Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol. 2010;10:111–22.
5. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 2007;17:118–26.
6. Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008;9:405–14.
7. Thai TH, Calado DP, Casola S, et al. Regulation of the germinal center response by microRNA-155. Science. 2007;316:604–8.
8. Rebane A, Runnel T, Aab A, et al. MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes. J Allergy Clin Immunol. 2014;134(4):836–47.
9. Xue Q, Guo ZY, Li W, et al. Human activated CD4(+) T lymphocytes increase IL-2 expression by downregulating microRNA-181c. Mol Immunol. 2011;48(4):592–9.
10. Poussin MA, Goluszko E, David CS, Franco JU, Christadoss P. HLA-DQ6 transgenic mice resistance to experimental autoimmune myasthenia gravis is linked to reduced acetylcholine receptor-specific IFN-γ, IL-2 and IL-10 production. J Autoimmun. 2001;17(3):175–80.
11. Paas-Rozner M, Sela M, Mozes E. The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes. Proc Natl Acad Sci USA. 2001;98(22):12642–7.
12. Zhang L, Dong LY, Li YJ, Hong Z, Wei WS. The microRNA miR-181c controls microglia-mediated neuronal apoptosis by suppressing tumor necrosis factor. J Neuroinflamm. 2012;6(9):211.
13. Drachman DB. Medical progress: myasthenia gravis. N Engl J Med. 1994;330:1797–810.
14. Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med. 1971;38:497–537.
15. Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol. 2005;174:6571e6.
16. Bikker A, Moret FM, Kruize AA, Bijlsma JW, Lafeber FP, van Roon JA. IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in CD4 T cells lacking the IL-7Rα. Rheumatology (Oxford). 2012;51(6):996–1005.
17. Ma X, Zhou J, Zhong Y, et al. Expression, regulation and function of microRNAs in multiple sclerosis. Int J Med Sci. 2014;11(8):810–8.
18. Haghikia A, Haghikia A, Hellwig K, et al. Regulated microRNAs in the CSF of patients with multiple sclerosis: a case–control study. Neurology. 2012;79(22):2166–70.
19. Abdelsadik A, Trad A. Toll-like receptors on the fork roads between innate and adaptive immunity. Hum Immunol. 2011;72(12):1188–93.
20. Zhang L, Li YJ, Wu XY, Hong Z, Wei WS. MicroRNA-181c negatively regulates the inflammatory response in oxygen–glucose-deprived microglia by targeting Toll-like receptor 4. J Neurochem. 2015;132(6):713–23.
21. Hartgring SA, Bijlsma JW, Lafeber FP, van Roon JA. Interleukin-7 induced immunopathology in arthritis. Ann Rheum Di. 2006;65(Suppl 3):iii69–74.
22. Hartgring SA, Willis CR, Bijlsma JW, Lafeber FP, van Roon JA. Interleukin-7-aggravated joint inflammation and tissue destruction in collagen-induced arthritis is associated with T-cell and B-cell activation. Arthritis Res Ther. 2012;14(3):R137.
23. Wang W, Milani M, Ostlie N, et al. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-γ are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J Immunol. 2007;178(11):7072–80.
24. Bai Y, Liu R, Huang D, et al. CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity. Eur J Immunol. 2008;38(7):1877–88.
25. Roche JC, Capablo JL, Larrad L, et al. Increased serum interleukin-17 levels in patients with myasthenia gravis. Muscle Nerve. 2011;44(2):278–80.
26. Zheng S, Dou C, Xin N, et al. Expression of interleukin-22 in myasthenia gravis. Scand J Immunol. 2013;78(1):98–107.
27. Sammicheli S, Ruffin N, Lantto R, Vivar N, Chiodi F, Rethi B. IL-7 modulates B cells survival and activation by inducing BAFF and CD70 expression in T cells. J Autoimmun. 2012;38(4):304–14.
28. Hartgring SA, Willis CR, Alcorn D, et al. Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis Rheum. 2010;62(9):2716–25.
29. Pickens SR, Chamberlain ND, Volin MV, et al. Characterization of interleukin-7 and interleukin-7 receptor in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2011;63(10):2884–93.
30. Totsuka T, Kanai T, Nemoto Y, et al. IL-7 Is essential for the development and the persistence of chronic colitis. J Immunol. 2007;178(8):4737–48.
31. Bonifati C, Trento E, Cordiali-Fei P, et al. Increased interleukin-7 concentrations in lesional skin and in the sera of patients with plaque-type psoriasis. Clin Immunol Immunopathol. 1997;83:41–4.
32. Rihl M, Kellner H, Kellner W, et al. Identification of interleukin-7 as a candidate disease mediator in spondylarthritis. Arthritis Rheum. 2008;58(11):3430–5.
33. Hofer J, Hofer S, Zlamy M, et al. Elevated proportions of recent thymic emigrants in children and adolescents with type 1 diabetes. Rejuvenation Res. 2009;12(5):311–20.
34. Yang Y, Xiao X, Li F, Du L, Kijlstra A, Yang P. Increased IL-7 expression in Vogt–Koyanagi–Harada disease. Invest Ophthalmol Vis Sci. 2012;53(2):1012–7.
35. Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol. 2011;11(5):330–42.
36. Saidijam M, Tootoonchi AS, Goodarzi MT, et al. Expression of interleukins 7 and 8 in peripheral blood mononuclear cells from patients with metabolic syndrome: a preliminary study. Indian J Med Res. 2014;140(2):238–43.
37. Harnaha J, Machen J, Wright M, Lakomy R, Styche A, Trucco M, Makaroun S, Giannoukakis N. Interleukin-7 is a survival factor for CD4+ CD25+ T-cells and is expressed by diabetes-suppressive dendritic cells. Diabetes. 2006;55(1):158–70.
38. Jana M, Mondal S, Jana A, Pahan K. Interleukin-12 (IL-12), but not IL-23, induces the expression of IL-7 in microglia and macrophages: implications for multiple sclerosis. Immunology. 2014;141(4):549–63.
39. Hu X, Cao Y, Meng Y, Hou M. A novel modulation of structural and functional changes of mouse bone marrow derived dendritic cells (BMDCs) by interleukin-2(IL-2). Hum Vaccin Immunother. 2015;11(2):516–21.